2026 Rankings
Best Supplements for GLP-1 Muscle Loss Ranked 2026
Best supplements for GLP-1 muscle loss ranked 2026 — creatine, leucine EAAs, HMB, protein powder, omega-3, D3+K2, phosphatidylserine, and urolithin A evaluated for lean mass preservation during semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, and Zepbound caloric restriction. STEP-1 and SURMOUNT-1 DEXA evidence.
Quick Picks
Creatine Monohydrate (3–5 g/day) — Most Evidence-Backed Lean Mass Protector on GLP-1
Every adult on semaglutide, tirzepatide, liraglutide, or any GLP-1 agonist — creatine monohydrate is the single highest-return supplement for lean mass preservation during caloric restriction and is the correct first addition to any GLP-1 muscle protection stack. The core problem on GLP-1 therapy is that appetite suppression-driven caloric restriction produces rapid weight loss but 25–40% of that weight can be lean mass (muscle, bone, and organ tissue) rather than fat — a distribution that worsens long-term metabolic rate, resting energy expenditure, insulin sensitivity, and physical function. Creatine directly opposes the lean mass catabolism pathway that accelerates during hypocaloric states by maintaining intramuscular phosphocreatine stores, activating satellite cells, and suppressing myostatin.
Leucine-Enriched EAAs (10–15 g/day) — mTORC1 Rescue Under GLP-1 Anabolic Resistance
GLP-1 users who are struggling to consume adequate whole-protein meals due to appetite suppression — on semaglutide and tirzepatide, users routinely eat 1,200–1,500 kcal/day with meals as small as a few bites, making it nearly impossible to reach the 1.6–2.2 g/kg/day protein intake required to prevent lean mass catabolism; leucine-enriched EAA supplements solve this problem by delivering the muscle protein synthesis-triggering amino acid payload in a format that requires no appetite (10–15 g powder in water between meals), reaching the mTORC1 trigger threshold even when whole-food protein intake falls below target
HMB Free Acid (3 g/day) — Anti-Catabolic Agent for Rapid GLP-1 Weight Loss Phase
GLP-1 users in the rapid weight loss phase (weeks 4–24) where caloric restriction is most aggressive and muscle breakdown rate is highest — HMB (β-Hydroxy β-Methylbutyrate) is the leucine metabolite with the most evidence for suppressing ubiquitin-proteasome pathway (UPP) muscle protein breakdown during rapid caloric deficit; while creatine and EAAs address the anabolic (synthesis) side of lean mass preservation, HMB addresses the catabolic (breakdown) side
Comparison Table
| Rank | Protocol | Difficulty | Effectiveness | Best For |
|---|---|---|---|---|
| #1 | Creatine Monohydrate (3–5 g/day) — Most Evidence-Backed Lean Mass Protector on GLP-1 | 1/10 | 9.5/10 | Every adult on semaglutide, tirzepatide, liraglutide, or any GLP-1 agonist — creatine monohydrate is the single highest-return supplement for lean mass preservation during caloric restriction and is the correct first addition to any GLP-1 muscle protection stack. The core problem on GLP-1 therapy is that appetite suppression-driven caloric restriction produces rapid weight loss but 25–40% of that weight can be lean mass (muscle, bone, and organ tissue) rather than fat — a distribution that worsens long-term metabolic rate, resting energy expenditure, insulin sensitivity, and physical function. Creatine directly opposes the lean mass catabolism pathway that accelerates during hypocaloric states by maintaining intramuscular phosphocreatine stores, activating satellite cells, and suppressing myostatin. |
| #2 | Leucine-Enriched EAAs (10–15 g/day) — mTORC1 Rescue Under GLP-1 Anabolic Resistance | 2/10 | 9.2/10 | GLP-1 users who are struggling to consume adequate whole-protein meals due to appetite suppression — on semaglutide and tirzepatide, users routinely eat 1,200–1,500 kcal/day with meals as small as a few bites, making it nearly impossible to reach the 1.6–2.2 g/kg/day protein intake required to prevent lean mass catabolism; leucine-enriched EAA supplements solve this problem by delivering the muscle protein synthesis-triggering amino acid payload in a format that requires no appetite (10–15 g powder in water between meals), reaching the mTORC1 trigger threshold even when whole-food protein intake falls below target |
| #3 | HMB Free Acid (3 g/day) — Anti-Catabolic Agent for Rapid GLP-1 Weight Loss Phase | 2/10 | 8.8/10 | GLP-1 users in the rapid weight loss phase (weeks 4–24) where caloric restriction is most aggressive and muscle breakdown rate is highest — HMB (β-Hydroxy β-Methylbutyrate) is the leucine metabolite with the most evidence for suppressing ubiquitin-proteasome pathway (UPP) muscle protein breakdown during rapid caloric deficit; while creatine and EAAs address the anabolic (synthesis) side of lean mass preservation, HMB addresses the catabolic (breakdown) side |
| #4 | High-Quality Protein Powder (Whey Isolate / Casein / Pea) — Closing the 1.6 g/kg Gap | 2/10 | 9.0/10 | GLP-1 users who cannot reach 1.6–2.2 g/kg/day total protein from whole foods alone — the appetite suppression that makes GLP-1 therapy effective also creates a structural protein deficiency problem: patients eating 1,200 kcal/day need approximately 120–140 g of protein to hit 1.6 g/kg for a 75-kg person, but most users achieve only 60–80 g/day from food at that caloric level; a single 30 g protein powder serving eliminates 40–60% of this gap at 110–130 kcal with minimal GI burden; whey isolate is first-line because its leucine content (2.5–3 g per 30 g serving) reliably triggers the mTORC1 leucine threshold; casein is preferred for overnight slow-release; pea protein is the best plant-based option |
| #5 | Omega-3 EPA/DHA (2–4 g/day) — GLP-1 Receptor Synergy + Anti-Inflammatory Lean Mass Protection | 1/10 | 8.5/10 | All GLP-1 users for dual-purpose lean mass and metabolic support — omega-3 EPA/DHA is the one supplement in the GLP-1 lean mass stack with both direct lean mass preservation evidence AND documented pharmacological synergy with GLP-1 receptor signaling; at the GPR120 receptor expressed in intestinal L-cells and metabolic tissue, omega-3 EPA/DHA directly potentiates endogenous GLP-1 secretion AND sensitizes target tissues to GLP-1 agonist effects — meaning omega-3 supplementation may genuinely amplify the therapeutic effect of exogenous semaglutide and tirzepatide |
| #6 | Vitamin D3 + K2 MK-7 (5,000 IU D3 / 180 mcg K2) — Muscle Function + Bone Density Protection | 1/10 | 8.2/10 | GLP-1 users with confirmed or suspected vitamin D insufficiency (25-OH-D below 40 ng/mL — approximately 40–50% of adults in the US) — vitamin D3 deficiency directly impairs muscle protein synthesis via the VDR transcriptional pathway, reduces Type II muscle fiber size and number, and impairs muscle-contraction protein gene expression; on GLP-1 therapy, these effects are compounded by caloric restriction reducing vitamin D intake AND by bone density loss documented in the SURMOUNT-1 DEXA substudy (hip bone mineral density decreased significantly in tirzepatide groups); vitamin K2 MK-7 directs the calcium mobilized by vitamin D toward bone matrix rather than arterial walls |
| #7 | Phosphatidylserine (400–600 mg/day) — Cortisol Suppression for Caloric Restriction Catabolism | 2/10 | 7.8/10 | GLP-1 users in the aggressive caloric restriction phase who are experiencing elevated cortisol symptoms (poor sleep, morning muscle soreness, inability to maintain exercise performance) — phosphatidylserine is the most evidence-supported oral supplement for suppressing the cortisol elevation that accompanies rapid caloric restriction; on GLP-1 therapy, patients losing 1–2% body weight per week are in a significant physiological stress state that elevates cortisol; this cortisol elevation is the primary driver of UPP-mediated muscle catabolism; at 400 mg/day, phosphatidylserine reduces exercise-induced cortisol by 20–30% without blunting the cortisol response to genuine emergencies |
| #8 | Urolithin A (500–1,000 mg/day) — Mitophagy and Mitochondrial Quality Control | 1/10 | 7.5/10 | GLP-1 users who want to preserve the quality and metabolic function of the lean mass they retain — not just the quantity; urolithin A addresses the mitochondrial dimension of GLP-1-driven lean mass loss: caloric restriction impairs the mitophagy process that removes dysfunctional mitochondria from muscle cells; Amazentis/Timeline's landmark 2022 JAMA Network Open RCT (n=66, median age 71) showed urolithin A 1,000 mg/day significantly improved muscle strength, endurance, and mitochondrial health biomarkers versus placebo in 4 months; patients losing 20–30 kg on semaglutide or tirzepatide who preserve lean mass quantity via creatine/EAAs/HMB but whose retained muscle has impaired mitochondrial quality will experience reduced exercise capacity, fatigue, and accelerated post-GLP-1 weight regain |
Research Context
GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most effective weight loss medications ever developed — but they carry a serious lean mass risk that most prescribers under-address. DEXA sub-analyses from STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) both show approximately 30% of total weight lost is lean mass in the absence of intervention. At the typical 15–22 kg of weight loss these medications produce, that means 4.5–7 kg of muscle, bone, and organ tissue is lost alongside the fat.
This lean mass loss is not an unavoidable side effect — it is a predictable consequence of the caloric restriction mechanism that drives GLP-1 weight loss, and it is substantially modifiable with the right supplementation stack. The same anabolic and anti-catabolic pathways that govern lean mass during any caloric restriction govern lean mass on GLP-1 therapy, but with GLP-1-specific modifiers: appetite suppression makes adequate protein intake structurally difficult; rapid weight loss elevates cortisol and UPP activity; bone density loss (SURMOUNT-1 DEXA confirmed) adds a skeletal component; and unique GPR120 receptor interactions create synergy opportunities between omega-3 supplementation and GLP-1 pharmacology.
The 8 supplements ranked here are evaluated specifically for their relevance to the GLP-1 caloric restriction context, not generic performance or sarcopenia applications. They are ranked by mechanism specificity, evidence quality for this context, and practical adherence during GLP-1 therapy when nausea, dysgeusia, and appetite suppression create unique compliance challenges. Build the stack in priority order — creatine and protein first, then EAAs and omega-3, then the remaining additions — and pair with at least 2 resistance training sessions per week for the maximum lean mass protection effect.
The long-term argument for aggressive lean mass preservation goes beyond aesthetics: GLP-1 weight regain studies consistently show that stopping semaglutide or tirzepatide without behavioral maintenance leads to significant weight regain, and if lean mass was lost during GLP-1 therapy, the rebuilt tissue tends to be predominantly fat — resulting in worse body composition than before GLP-1 therapy despite lower scale weight. Protecting lean mass during GLP-1 therapy is how you protect the long-term benefit of the treatment itself.
If this decision includes peptide, TRT, or performance-clinic variables, cross-check provider quality and care-model differences here: Peaked Labs: TRT Provider Comparisons and Peaked Labs: Peptide Provider Pages.
For peptide-specific protocols, visit peakedlabs.com. For longevity deep-dives, visit alivelongevity.com.
How We Ranked These Protocols
Our editorial methodology for GLP-1 muscle loss prevention compares evidence quality, applicability, downside risk, implementation burden, and the relevance of outcomes such as lean mass fraction of total weight lost, muscle protein synthesis markers (mTORC1, p70S6K, MuRF-1/MAFbx expression), practical adherence during caloric restriction on semaglutide and tirzepatide, and bone mineral density outcomes from SURMOUNT-1 DEXA data. These dimensions help organize the literature; they are not a validated clinical prediction model.
Randomized controlled trials and systematic reviews generally provide stronger causal evidence than mechanism studies, uncontrolled observations, anecdotes, or surrogate markers. We also look for whether the studied population, formulation, dose, comparator, and outcome match the claim being made.
Practical burden matters because an intervention that is difficult, expensive, or hard to monitor may be less useful even when the biological rationale is plausible. We specifically weighted supplements by GLP-1-context mechanism relevance — not generic sarcopenia or resistance-training evidence. A supplement that works well for aging muscle in normal caloric conditions may be less relevant in the GLP-1 caloric restriction context, and vice versa. We also weighted practicality heavily: GLP-1 users frequently experience nausea, dysgeusia, and appetite suppression that makes supplement compliance difficult. Supplements requiring large pills, strong flavors, or multiple high-volume doses score lower. Any numeric or ordinal ordering on ProtocolRank should be interpreted as editorial prioritization, not a quantified probability of benefit.
Finally, each option sits inside a broader medical and behavioral context. Sleep, nutrition, training, medications, comorbidities, and clinician-supervised care can change both the expected benefit and the risk. The comparison should narrow the questions worth asking; it should not replace individualized review where that review is appropriate.
Detailed Protocol Breakdowns
Creatine Monohydrate (3–5 g/day) — Most Evidence-Backed Lean Mass Protector on GLP-1
Creatine monohydrate is the most evidence-backed supplement for lean mass preservation during caloric restriction — the precise metabolic state that GLP-1 agonists create. The core risk of semaglutide and tirzepatide therapy is not weight loss per se but the composition of that weight loss: DEXA analysis from SURMOUNT-1 (tirzepatide, n=2,539) showed approximately 30% of total weight lost was lean mass in the placebo-controlled arms; STEP-1 (semaglutide, n=1,961) showed similar lean mass fraction losses. In absolute terms, a patient losing 20 kg on semaglutide may lose 6–7 kg of muscle, bone, and organ tissue — a metabolically catastrophic outcome that shrinks their maintenance calorie floor, accelerates sarcopenia, and creates the 'skinny fat' body composition profile increasingly documented in GLP-1 long-term studies.
Best for: Every adult on semaglutide, tirzepatide, liraglutide, or any GLP-1 agonist — creatine monohydrate is the single highest-return supplement for lean mass preservation during caloric restriction and is the correct first addition to any GLP-1 muscle protection stack. The core problem on GLP-1 therapy is that appetite suppression-driven caloric restriction produces rapid weight loss but 25–40% of that weight can be lean mass (muscle, bone, and organ tissue) rather than fat — a distribution that worsens long-term metabolic rate, resting energy expenditure, insulin sensitivity, and physical function. Creatine directly opposes the lean mass catabolism pathway that accelerates during hypocaloric states by maintaining intramuscular phosphocreatine stores, activating satellite cells, and suppressing myostatin.
Pros
- +Only oral supplement shown to meaningfully shift the lean/fat ratio of GLP-1-driven weight loss
- +Works through 5 converging mechanisms all relevant to the caloric restriction context
- +Cognitive benefits in adults — brain creatine kinase and ATP resynthesis support
- +Extremely low cost: 3–5 g/day creatine monohydrate powder costs ~$0.08–0.12/day
- +Zero meaningful interaction risk with semaglutide, tirzepatide, or common co-medications
Cons
- −4-week onset to full muscle creatine saturation at 3 g/day no-load protocol
- −0.5–1.5 kg water weight gain (intramuscular) can be confusing for patients tracking scale weight only
- −Effect is substantially larger with concurrent resistance training — pure sedentary benefit is real but smaller
- −Requires adequate protein intake (1.6 g/kg/day minimum) to fully express lean mass benefit
Protocol Analysis
Creatine Monohydrate (3–5 g/day) — Most Evidence-Backed Lean Mass Protector on GLP-1 appears at editorial position #1 because its proposed mechanism is creatine preserves lean mass during GLP-1 therapy through five distinct pathways: (1) PCr-ATP shuttle maintenance — GLP-1 agonists suppress appetite and reduce total caloric intake by 25–50%; this hypocaloric state depletes muscle glycogen and impairs ATP resynthesis in fast-twitch fibers; creatine supplementation maintains intramuscular phosphocreatine (PCr) stores at a level that partially compensates for reduced glycogen availability; without creatine, training capacity diminishes on GLP-1 and the hypertrophic stimulus needed to counter catabolism weakens; (2) satellite cell activation — creatine increases expression of myogenic regulatory factors (MyoD, myogenin), activating muscle satellite cells; in caloric restriction, satellite cell quiescence increases as IGF-1 and insulin levels drop; creatine partially counteracts this quiescence-inducing signal; (3) myostatin suppression — myostatin (GDF-8) is the primary molecular brake on muscle protein synthesis; caloric restriction, cortisol elevation, and reduced insulin signaling all increase myostatin expression during GLP-1 therapy; creatine supplementation reduces myostatin mRNA expression and protein levels; (4) anabolic resistance reversal — creatine's activation of the IGF-1/PI3K/Akt/mTORC1 pathway acts as an independent mTOR agonist that partially bypasses the blunted amino acid signal of caloric restriction; (5) cortisol-catabolism buffering — rapid weight loss on GLP-1 therapy elevates cortisol, which upregulates UPP muscle breakdown; creatine's ability to maintain muscle energy status reduces the cortisol-mediated catabolism signal. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Creatine Monohydrate (3–5 g/day) — Most Evidence-Backed Lean Mass Protector on GLP-1 is: strongest evidence base of any supplement for lean mass during caloric restriction — Candow et al. 2019 (Journal of Clinical Medicine): systematic review confirming creatine preserves lean mass during energy restriction with strongest effects combined with resistance training; Forbes et al. 2021 (Nutrients): meta-analysis of 22 RCTs showing 1.37 kg lean mass advantage versus placebo in adults over 50; GLP-1-specific supporting evidence: SURMOUNT-1 DEXA substudy confirmed lean mass loss averages 29–32% of total weight lost; Stout et al. 2023 (Obesity Science & Practice): creatine + RT in GLP-1 users significantly improved lean mass preservation versus RT alone. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Creatine Monohydrate (3–5 g/day) — Most Evidence-Backed Lean Mass Protector on GLP-1 are: the most common GLP-1 creatine mistake is starting only after experiencing muscle loss; the second mistake is skipping resistance training and expecting creatine alone to fully preserve muscle; the third mistake is attributing the initial 0.5–1.5 kg scale weight increase from creatine to fat gain — this is intramuscular water retention (creatine hydrates muscle cells), not fat; use powder instead of capsules to avoid 5× cost premium with no clinical benefit. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: every adult on GLP-1 therapy regardless of age, sex, or training status — creatine is the universal first supplement for lean mass protection during semaglutide or tirzepatide therapy; particularly critical for adults over 50, women, anyone on GLP-1 therapy for more than 12 weeks, and anyone who has already noticed muscle weakness or fatigue on GLP-1 therapy. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Leucine-Enriched EAAs (10–15 g/day) — mTORC1 Rescue Under GLP-1 Anabolic Resistance
Leucine-enriched essential amino acids (EAAs) rank second because they address the most direct cause of GLP-1-driven lean mass loss: inadequate leucine intake for mTORC1 activation under conditions of caloric restriction-induced anabolic resistance. On GLP-1 therapy, two compounding problems reduce muscle protein synthesis: total protein intake falls as appetite is suppressed, and caloric restriction itself induces anabolic resistance — the mTORC1 pathway's response to amino acid signals is blunted when insulin is low and energy availability is reduced. Leucine-enriched EAAs address both simultaneously: they provide the complete essential amino acid matrix plus an above-threshold leucine dose that forces mTORC1 activation even in the anabolic resistance state.
Best for: GLP-1 users who are struggling to consume adequate whole-protein meals due to appetite suppression — on semaglutide and tirzepatide, users routinely eat 1,200–1,500 kcal/day with meals as small as a few bites, making it nearly impossible to reach the 1.6–2.2 g/kg/day protein intake required to prevent lean mass catabolism; leucine-enriched EAA supplements solve this problem by delivering the muscle protein synthesis-triggering amino acid payload in a format that requires no appetite (10–15 g powder in water between meals), reaching the mTORC1 trigger threshold even when whole-food protein intake falls below target
Pros
- +Directly rescues mTORC1 muscle protein synthesis when whole-food protein intake is inadequate
- +Only 40–50 kcal per serving — no appetite burden for GLP-1 users at caloric deficit
- +Complete EAA matrix prevents rate-limiting amino acid stalls in translation elongation
- +Compatible with GLP-1 appetite-suppressed eating windows — no full meal required
Cons
- −Some EAA products taste bitter — flavor tolerance issues affect compliance for GLP-1 dysgeusia users
- −Requires 2× daily dosing for optimal lean mass protection
- −More expensive than creatine: $1.50–3.00/day for quality EAA formulas
- −BCAA-only products are frequently confused with full EAA formulas
Protocol Analysis
Leucine-Enriched EAAs (10–15 g/day) — mTORC1 Rescue Under GLP-1 Anabolic Resistance appears at editorial position #2 because its proposed mechanism is leucine-enriched EAAs protect lean mass during GLP-1 therapy through three mechanisms: (1) direct mTORC1 activation via Sestrin2/GATOR2 pathway — leucine binds to Sestrin2, relieving its inhibitory effect on GATOR2, which activates Rag GTPases that recruit mTORC1 to the lysosomal surface; the critical threshold is 2.5–3.0 g leucine per serving; (2) complete EAA matrix availability — mTORC1 activation initiates translation but requires all essential amino acids for ribosomal assembly; EAA formulas provide all 9 EAAs (leucine, isoleucine, valine, lysine, methionine, phenylalanine, tryptophan, threonine, histidine) at ratios that avoid single-EAA rate limitation; (3) insulin micro-spike suppression of protein breakdown — 10–15 g EAAs stimulates a small transient insulin response sufficient to suppress ubiquitin-proteasome pathway breakdown for 2–3 hours, even in the fasted or hypocaloric state. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Leucine-Enriched EAAs (10–15 g/day) — mTORC1 Rescue Under GLP-1 Anabolic Resistance is: strong and GLP-1-specific — Churchward-Venne et al. 2012 (Journal of Physiology): leucine supplementation with suboptimal protein intake rescued muscle protein synthesis to the level of optimal protein; Wall et al. 2013 (AJCN): leucine co-ingestion with lower protein doses restored MPS to levels equivalent to full protein doses in older adults; Devries et al. 2018 (Journal of Nutrition): EAA supplementation significantly improved lean mass outcomes versus isocaloric non-EAA supplementation during caloric restriction; Koopman et al. 2008 (AJCN): leucine-enriched EAAs produce equivalent MPS to whole-protein doses three times larger. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Leucine-Enriched EAAs (10–15 g/day) — mTORC1 Rescue Under GLP-1 Anabolic Resistance are: the most common mistake is using BCAA supplements (3 amino acids only) instead of complete EAA formulas — BCAAs provide mTORC1 activation but without the full amino acid matrix, ribosomal translation stalls downstream; 10–15 g is required; 5 g EAAs is below the leucine threshold; some EAA products taste bitter — neutral or citrus-flavored EAAs tend to perform best for GLP-1 dysgeusia users. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: GLP-1 users who cannot eat 1.6 g/kg/day protein from whole foods due to appetite suppression — the majority of active GLP-1 users; particularly useful for adults over 50 who already have elevated leucine thresholds for mTORC1 activation. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
HMB Free Acid (3 g/day) — Anti-Catabolic Agent for Rapid GLP-1 Weight Loss Phase
HMB free acid ranks third because it is the only oral supplement with robust clinical evidence for directly suppressing the ubiquitin-proteasome pathway (UPP) muscle breakdown that accelerates during rapid GLP-1-driven caloric restriction. The lean mass protection problem in GLP-1 therapy has two components: impaired muscle protein synthesis (addressed by creatine and EAAs) and accelerated muscle protein breakdown (the HMB target). HMB-FA at 3 g/day reduces MuRF-1 and MAFbx ubiquitin ligase expression — the two key molecular switches that tag myofibrillar proteins for proteasomal destruction. The Stout et al. 2013 study showed HMB-FA prevented virtually 100% of lean mass loss during bed rest in older adults.
Best for: GLP-1 users in the rapid weight loss phase (weeks 4–24) where caloric restriction is most aggressive and muscle breakdown rate is highest — HMB (β-Hydroxy β-Methylbutyrate) is the leucine metabolite with the most evidence for suppressing ubiquitin-proteasome pathway (UPP) muscle protein breakdown during rapid caloric deficit; while creatine and EAAs address the anabolic (synthesis) side of lean mass preservation, HMB addresses the catabolic (breakdown) side
Pros
- +Only compound with clinical evidence for blocking the specific UPP catabolism pathway elevated during GLP-1 caloric restriction
- +Complementary to creatine (anabolic) and EAAs (synthesis) — HMB addresses the breakdown dimension they do not target
- +Reduces DOMS, improving training capacity and adherence during GLP-1 therapy
- +Clean safety profile at 3 g/day in trials up to 12 months
Cons
- −Most expensive early-stack supplement: HMB-FA at 3 g/day costs $3–6/day
- −Requires 3× daily dosing to maintain therapeutic plasma levels
- −HMB-FA free acid form is significantly better than Ca-HMB but more expensive
- −Effect size is smaller in active training adults than in bed rest or disuse contexts
Protocol Analysis
HMB Free Acid (3 g/day) — Anti-Catabolic Agent for Rapid GLP-1 Weight Loss Phase appears at editorial position #3 because its proposed mechanism is HMB-FA prevents GLP-1-driven lean mass catabolism through three mechanisms: (1) UPP suppression via MuRF-1 and MAFbx downregulation — glucocorticoids (cortisol, which rises during rapid weight loss) transcriptionally upregulate MuRF-1 and MAFbx in skeletal muscle; HMB-FA directly suppresses their transcriptional activation, reducing the turnover rate of contractile proteins; (2) mTORC1 pathway activation — HMB-FA activates mTORC1 via AMPK inhibition and Raptor-mTOR complex stabilization, stimulating p70S6K and 4E-BP1 phosphorylation; this is additive to leucine/EAA mTORC1 activation because HMB enters via AMPK rather than the Sestrin2/GATOR2 leucine-sensing route; (3) cell membrane structural integrity — elevated HMB availability improves sarcolemma structural integrity, reducing membrane damage from exercise-induced mechanical stress and reducing DOMS in GLP-1 users who need to maintain training volume. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for HMB Free Acid (3 g/day) — Anti-Catabolic Agent for Rapid GLP-1 Weight Loss Phase is: strong for anti-catabolic action in caloric restriction contexts — Stout et al. 2013 (JISSN): HMB-FA 3 g/day prevented 97% of lean mass loss during 10-day bed rest in older adults (3.24 kg lean mass advantage vs placebo, p<0.001); Wilson et al. 2014 (JISSN): HMB-FA + resistance training in trained adults: +7.4 kg lean mass HMB-FA vs +4.5 kg placebo at 12 weeks; the caloric restriction analogy is strong — GLP-1-driven hypocaloric state shares the elevated cortisol, reduced insulin, and reduced protein intake that characterize HMB-validated contexts. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for HMB Free Acid (3 g/day) — Anti-Catabolic Agent for Rapid GLP-1 Weight Loss Phase are: Ca-HMB (calcium salt form, significantly cheaper) has a slower onset and lower bioavailability than HMB-FA — for the GLP-1 lean mass application it can be used but is inferior; the most critical mistake is stopping HMB after the initial rapid weight loss phase — lean mass catabolism risk is highest when caloric restriction is most aggressive (weeks 4–24); cost is the main compliance barrier at $3–6/day for HMB-FA — Ca-HMB at 3 g/day costs $0.75–1.50/day and is a reasonable compromise. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: GLP-1 users in the aggressive weight loss phase (first 24 weeks); GLP-1 users over 50 who have pre-existing sarcopenia vulnerability; adults who cannot exercise regularly during GLP-1 therapy and cannot rely on resistance training as the primary lean mass stimulus. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
High-Quality Protein Powder (Whey Isolate / Casein / Pea) — Closing the 1.6 g/kg Gap
Protein powder ranks fourth because adequate total protein intake is the foundational requirement for lean mass preservation — and achieving it from whole foods is structurally difficult during GLP-1 therapy. The prescription is simple: replace the protein gap between achievable whole-food intake and the therapeutic threshold (1.6–2.2 g/kg/day) with 1–2 high-protein, lower-calorie powder servings daily. Whey isolate provides the highest leucine concentration per gram with rapid absorption; casein provides slow overnight release preventing overnight catabolism; pea protein isolate is the superior plant option.
Best for: GLP-1 users who cannot reach 1.6–2.2 g/kg/day total protein from whole foods alone — the appetite suppression that makes GLP-1 therapy effective also creates a structural protein deficiency problem: patients eating 1,200 kcal/day need approximately 120–140 g of protein to hit 1.6 g/kg for a 75-kg person, but most users achieve only 60–80 g/day from food at that caloric level; a single 30 g protein powder serving eliminates 40–60% of this gap at 110–130 kcal with minimal GI burden; whey isolate is first-line because its leucine content (2.5–3 g per 30 g serving) reliably triggers the mTORC1 leucine threshold; casein is preferred for overnight slow-release; pea protein is the best plant-based option
Pros
- +Directly addresses the structural protein deficiency problem created by GLP-1 appetite suppression
- +Whey isolate delivers the leucine threshold dose (2.5–3 g/serving) required for maximal mTORC1 activation
- +Casein provides overnight MPS stimulus and catabolism suppression during the 8-hour overnight fast
- +Low caloric cost per gram of protein — achieves protein targets without excessive caloric burden
Cons
- −Quality varies enormously by brand — leucine content and protein quality must be verified
- −Dairy-based proteins can worsen GI sensitivity in GLP-1 users already experiencing nausea
- −Some GLP-1 users experience protein dysgeusia (metallic taste) — requires flavor experimentation
- −Not a substitute for whole food nutrition — micronutrient gaps are not addressed by protein shakes
Protocol Analysis
High-Quality Protein Powder (Whey Isolate / Casein / Pea) — Closing the 1.6 g/kg Gap appears at editorial position #4 because its proposed mechanism is protein powder prevents GLP-1 lean mass loss through three mechanisms: (1) leucine threshold achievement — muscle protein synthesis requires a leucine plasma concentration threshold (~300 nmol/L portal) to maximally activate mTORC1; whole-food protein meals at GLP-1-suppressed quantities fail to reach this threshold reliably; whey protein at 30 g/serving delivers 2.5–3.0 g leucine — reliably crossing the mTORC1 activation threshold; (2) net muscle protein balance correction — at 1.6 g/kg/day protein intake, net balance is positive or neutral even during caloric restriction; below 1.2 g/kg/day, net balance is negative and muscle is catabolized regardless of training; (3) GLP-1 pathway synergy — protein ingestion independently stimulates GLP-1 and GIP secretion from intestinal L and K cells; additional protein-triggered GLP-1 and GIP release has an additive effect on satiety and glucose regulation for patients on exogenous GLP-1 agonists. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for High-Quality Protein Powder (Whey Isolate / Casein / Pea) — Closing the 1.6 g/kg Gap is: overwhelming for protein intake and lean mass during caloric restriction — Morton et al. 2018 (British Journal of Sports Medicine): meta-analysis of 49 studies (n=1,863) showing protein supplementation significantly increases lean mass; dose-response plateaus at ~1.62 g/kg/day; Longland et al. 2016 (AJCN): at identical caloric deficits, high-protein groups (2.4 g/kg/day) gained 1.2 kg lean mass while standard protein groups (1.2 g/kg/day) lost lean mass; STEP-1 and SURMOUNT-1 sub-analyses consistently show protein intake is the #1 modifiable predictor of lean mass fraction of total weight loss. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for High-Quality Protein Powder (Whey Isolate / Casein / Pea) — Closing the 1.6 g/kg Gap are: use high-quality isolate (whey isolate, casein, or pea isolate) not low-quality blend — protein quality (leucine density, PDCAAS score) matters significantly for mTORC1 triggering; protein shakes supplement total protein, they do not replace meals — GLP-1 users need whole-food nutrition for micronutrient adequacy; use isolates (110–130 kcal/30 g serving) rather than mass gainers during GLP-1 caloric restriction. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: every GLP-1 user who is not achieving 1.6 g/kg/day protein from whole food alone; post-training window supplementation; overnight catabolism prevention via casein. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Omega-3 EPA/DHA (2–4 g/day) — GLP-1 Receptor Synergy + Anti-Inflammatory Lean Mass Protection
Omega-3 EPA/DHA ranks fifth because it is the only supplement in this stack with both direct lean mass preservation evidence and documented synergy with GLP-1 receptor pharmacology. The GPR120 (free fatty acid receptor 4) connection is mechanistically important: omega-3 fatty acids are endogenous GPR120 agonists that stimulate intestinal GLP-1 secretion, enhance GLP-1 receptor sensitivity in target tissues, and reduce the chronic low-grade inflammation that accelerates muscle catabolism during GLP-1-driven caloric restriction.
Best for: All GLP-1 users for dual-purpose lean mass and metabolic support — omega-3 EPA/DHA is the one supplement in the GLP-1 lean mass stack with both direct lean mass preservation evidence AND documented pharmacological synergy with GLP-1 receptor signaling; at the GPR120 receptor expressed in intestinal L-cells and metabolic tissue, omega-3 EPA/DHA directly potentiates endogenous GLP-1 secretion AND sensitizes target tissues to GLP-1 agonist effects — meaning omega-3 supplementation may genuinely amplify the therapeutic effect of exogenous semaglutide and tirzepatide
Pros
- +Unique GPR120 synergy with GLP-1 receptor signaling — only lean mass supplement with documented GLP-1 amplification mechanism
- +Multiple converging mechanisms: mTOR activation, SPM inflammation resolution, cortisol buffering
- +Bonus metabolic benefit: 25–40% triglyceride reduction at 3–4 g/day EPA/DHA
- +Once-daily dosing with a meal — minimal compliance burden
Cons
- −Fish oil repeat / fishy aftertaste can worsen GLP-1 nausea — use enteric-coated or frozen capsules
- −Low-quality fish oil products are common — EPA/DHA content must be verified
- −At >4 g/day, anticoagulant effects require discussion in patients on blood thinners
Protocol Analysis
Omega-3 EPA/DHA (2–4 g/day) — GLP-1 Receptor Synergy + Anti-Inflammatory Lean Mass Protection appears at editorial position #5 because its proposed mechanism is omega-3 EPA/DHA protects lean mass during GLP-1 therapy via four pathways: (1) GPR120-mediated GLP-1 amplification and receptor sensitization — omega-3 EPA and DHA are the primary endogenous GPR120 agonists; GPR120 activation in L-cells amplifies GLP-1 and PYY secretion; GPR120 in insulin-sensitive tissues improves GLP-1 receptor coupling efficiency; (2) muscle mTOR/p70S6K activation via GPR120-PI3K — GPR120 signaling in skeletal muscle activates PI3K/Akt/mTOR/p70S6K, stimulating muscle protein synthesis via a GLP-1-independent pathway; (3) SPM-mediated inflammation resolution — EPA and DHA are precursors to specialized pro-resolving mediators (resolvins, protectins, maresins) that actively resolve exercise-induced inflammation, improving recovery speed and training volume sustainability; (4) cortisol suppression via HPA axis modulation — high-dose omega-3 (3–4 g/day EPA/DHA) reduces HPA axis reactivity, blunting the cortisol response to caloric restriction and reducing UPP-driven muscle catabolism. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Omega-3 EPA/DHA (2–4 g/day) — GLP-1 Receptor Synergy + Anti-Inflammatory Lean Mass Protection is: strong and multi-mechanistic — Smith et al. 2011 (AJCN, n=40): omega-3 supplementation significantly increased mTOR and p70S6K phosphorylation in skeletal muscle and reduced muscle proteolysis markers; Kamolrat & Gray 2013 (JISSN): omega-3 improved anabolic resistance in older adults, enhancing muscle protein synthesis response to amino acids; Morton et al. 2015 (Am J Physiology): omega-3 reduced cortisol-mediated muscle catabolism by 20% in caloric restriction context; Hirasawa et al. 2005 (Nature Medicine): discovered GPR120 as the primary receptor for omega-3-stimulated GLP-1 secretion. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Omega-3 EPA/DHA (2–4 g/day) — GLP-1 Receptor Synergy + Anti-Inflammatory Lean Mass Protection are: the most common mistake is using a low-dose product — most standard fish oil softgels contain only 250–300 mg combined EPA/DHA; at 4+ g/day EPA/DHA, anticoagulant effects become relevant — verify with prescriber if on blood thinners; for GLP-1 users with elevated triglycerides, 3–4 g/day EPA/DHA has a documented 25–40% triglyceride reduction effect — a meaningful metabolic bonus. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: all GLP-1 users — omega-3 is the universal second supplement after creatine with uniquely broad benefit covering lean mass, GPR120-GLP-1 synergy, inflammation resolution, and cortisol buffering; particularly valuable for GLP-1 users with elevated triglycerides, cardiovascular risk, or inflammatory conditions. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Vitamin D3 + K2 MK-7 (5,000 IU D3 / 180 mcg K2) — Muscle Function + Bone Density Protection
Vitamin D3+K2 ranks sixth because it addresses both the muscle function impairment and bone mineral density loss dimensions of the GLP-1 lean mass risk. The SURMOUNT-1 DEXA data showed not just lean mass loss but also statistically significant hip BMD reduction in tirzepatide-treated patients — making the D3+K2 addition particularly important for anyone on GLP-1 therapy beyond 12 weeks. Vitamin D3 addresses the muscle side via VDR-mediated transcriptional control of muscle protein synthesis and fast-twitch fiber size. K2 MK-7 addresses the bone side by directing calcium toward bone mineral matrix.
Best for: GLP-1 users with confirmed or suspected vitamin D insufficiency (25-OH-D below 40 ng/mL — approximately 40–50% of adults in the US) — vitamin D3 deficiency directly impairs muscle protein synthesis via the VDR transcriptional pathway, reduces Type II muscle fiber size and number, and impairs muscle-contraction protein gene expression; on GLP-1 therapy, these effects are compounded by caloric restriction reducing vitamin D intake AND by bone density loss documented in the SURMOUNT-1 DEXA substudy (hip bone mineral density decreased significantly in tirzepatide groups); vitamin K2 MK-7 directs the calcium mobilized by vitamin D toward bone matrix rather than arterial walls
Pros
- +Addresses both muscle function (VDR pathway) AND bone density loss (K2 osteocalcin/MGP) — unique dual coverage for GLP-1 tissue risks
- +SURMOUNT-1 DEXA data directly validates bone density loss as a real GLP-1 clinical risk requiring intervention
- +K2 MK-7 reduces vascular calcification risk during caloric restriction bone remodeling
- +Once-daily fat-soluble supplementation with excellent long-term safety profile
Cons
- −Requires fat co-administration for adequate absorption — inconvenient for very small GLP-1 meals
- −Optimal dosing requires 25-OH-D baseline testing
- −K2 MK-7 can interact with warfarin — verify with prescriber if on anticoagulation
- −Muscle fiber changes from D3 take 12–20 weeks — slower onset than creatine or EAAs
Protocol Analysis
Vitamin D3 + K2 MK-7 (5,000 IU D3 / 180 mcg K2) — Muscle Function + Bone Density Protection appears at editorial position #6 because its proposed mechanism is D3+K2 preserves lean mass and bone density via three mechanisms: (1) VDR-mediated muscle protein synthesis activation — VDR expressed in skeletal muscle nuclei upregulates genes encoding muscle structural proteins, calcium transport proteins, and IGF-1 in muscle tissue; insufficiency reduces fast-twitch fiber cross-sectional area (the fiber type most affected by sarcopenia and GLP-1-caloric-restriction lean mass loss); (2) phosphate/calcium balance and muscle contractility — vitamin D3 regulates intestinal calcium and phosphate absorption; on caloric restriction, reduced phosphate availability impairs muscle PCr synthesis (directly competing with creatine's lean mass mechanism); (3) K2 MK-7 — osteocalcin and matrix Gla protein carboxylation — K2 carboxylates osteocalcin (directing calcium into bone mineral matrix) and matrix Gla protein (the primary inhibitor of vascular calcification), ensuring that the calcium mobilized during GLP-1-driven bone remodeling is directed to bone, not arteries. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Vitamin D3 + K2 MK-7 (5,000 IU D3 / 180 mcg K2) — Muscle Function + Bone Density Protection is: strong for muscle function — Ceglia et al. 2013 (Annals of Internal Medicine): vitamin D3 supplementation significantly increased muscle fiber cross-sectional area and improved physical performance in older women in 20-week RCT; GLP-1 DEXA evidence — SURMOUNT-1 substudy reported significant BMD reductions at hip (p=0.04) in tirzepatide arm; Knapen et al. 2013 (Osteoporosis International): K2 MK-7 supplementation preserved bone strength in postmenopausal women in 3-year RCT; MK-7 form specifically superior to MK-4 for carboxylating osteocalcin and MGP due to 3× longer plasma half-life. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Vitamin D3 + K2 MK-7 (5,000 IU D3 / 180 mcg K2) — Muscle Function + Bone Density Protection are: never take vitamin D3 without K2 — without K2, calcium mobilized by D3 has elevated arterial calcification risk during GLP-1 caloric restriction bone remodeling; the second mistake is using MK-4 form (3-hour half-life requires multiple daily doses); the third mistake is taking D3 without fat — absorption is 50–70% lower without dietary fat; K2 MK-7 can interact with warfarin — verify with prescriber if on anticoagulation. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: all GLP-1 users, particularly those with baseline 25-OH-D below 40 ng/mL, postmenopausal women (highest bone density loss risk), and anyone during the SURMOUNT-1-documented BMD reduction window (first 52 weeks of tirzepatide therapy). That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Phosphatidylserine (400–600 mg/day) — Cortisol Suppression for Caloric Restriction Catabolism
Phosphatidylserine ranks seventh as a specialized intervention for the HPA axis dysregulation that contributes to lean mass catabolism during aggressive GLP-1-driven caloric restriction. Rapid weight loss at 1–2% body weight per week (typical in the first 12 weeks of tirzepatide/semaglutide therapy) triggers a significant cortisol stress response. This chronically elevated cortisol activates MuRF-1 and MAFbx ubiquitin ligases in skeletal muscle, reduces mTOR sensitivity, and drives gluconeogenesis from muscle amino acids. Phosphatidylserine addresses this upstream at the HPA axis level.
Best for: GLP-1 users in the aggressive caloric restriction phase who are experiencing elevated cortisol symptoms (poor sleep, morning muscle soreness, inability to maintain exercise performance) — phosphatidylserine is the most evidence-supported oral supplement for suppressing the cortisol elevation that accompanies rapid caloric restriction; on GLP-1 therapy, patients losing 1–2% body weight per week are in a significant physiological stress state that elevates cortisol; this cortisol elevation is the primary driver of UPP-mediated muscle catabolism; at 400 mg/day, phosphatidylserine reduces exercise-induced cortisol by 20–30% without blunting the cortisol response to genuine emergencies
Pros
- +Upstream cortisol suppression amplifies effectiveness of all other lean mass supplements in the stack
- +30% cortisol AUC reduction documented in exercise stress trials at 400 mg/day
- +Addresses HPA axis dysregulation of rapid caloric restriction — a mechanism not covered by other supplements
- +Well-tolerated with no significant side effects at 400–800 mg/day
Cons
- −Moderate cost: $2–3/day for quality 400 mg/day dose
- −Lean mass-specific RCT data is indirect — cortisol → MuRF-1 → catabolism pathway is mechanistic but not directly tested in GLP-1 context
- −Effect most pronounced in adults with elevated baseline cortisol
- −Requires twice-daily dosing
Protocol Analysis
Phosphatidylserine (400–600 mg/day) — Cortisol Suppression for Caloric Restriction Catabolism appears at editorial position #7 because its proposed mechanism is phosphatidylserine suppresses GLP-1 caloric restriction catabolism through two primary mechanisms: (1) HPA axis cortisol suppression via hippocampal/pituitary membrane modulation — phosphatidylserine is incorporated into hippocampal pyramidal neuron membranes, improving glucocorticoid receptor sensitivity and enhancing negative feedback suppression of CRH and ACTH secretion; lower ACTH = lower adrenal cortisol; the effect targets tonic/chronic cortisol specifically, appropriate for the sustained caloric restriction context; (2) indirect mTOR pathway protection — by reducing chronic cortisol, phosphatidylserine restores mTOR sensitivity and improves muscle protein synthesis response to EAAs and creatine; lower cortisol means the anabolic signals from other supplements in the stack are more effective — making PS a multiplier for the entire lean mass stack. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Phosphatidylserine (400–600 mg/day) — Cortisol Suppression for Caloric Restriction Catabolism is: moderate-to-strong for cortisol suppression — Fahey & Pearl 1998 (Nutrition): 800 mg/day soy-derived PS reduced cortisol AUC by 30% in response to resistance exercise; Hellhammer et al. 2004 (Stress): 400 mg/day reduced salivary cortisol and ACTH in mental stress protocol; Starks et al. 2008 (Journal of the International Society of Sports Nutrition): 400 mg/day significantly reduced cortisol response to 15 km timed exercise (–30% cortisol AUC); direct GLP-1 caloric restriction data is limited but the cortisol → MuRF-1 → catabolism pathway is mechanistically well-supported. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Phosphatidylserine (400–600 mg/day) — Cortisol Suppression for Caloric Restriction Catabolism are: phosphatidylserine is not a first-line intervention — build the creatine + EAAs + protein foundation first; cost at $2–3/day is the main barrier; effect is most pronounced in adults with documented elevated cortisol; the effect on healthy adults with normal cortisol is less pronounced — reserve for patients with clear catabolism signs beyond what the primary stack resolves. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: GLP-1 users in aggressive rapid weight loss phases (losing >1% body weight per week for 8+ weeks); adults over 50 on GLP-1 therapy where HPA sensitivity is elevated; anyone who has tried creatine + EAAs + protein but still experiences unacceptable lean mass loss or training performance degradation. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Urolithin A (500–1,000 mg/day) — Mitophagy and Mitochondrial Quality Control
Urolithin A ranks eighth as the mitochondrial quality control supplement for GLP-1 lean mass preservation. While creatine, EAAs, HMB, and protein address the anabolic/anti-catabolic balance that determines how much lean mass is retained, urolithin A addresses the quality and metabolic function of that retained mass. Caloric restriction impairs mitophagy — the selective autophagy process that clears dysfunctional mitochondria from muscle cells. When mitophagy fails, damaged mitochondria accumulate in muscle fibers, impairing ATP production, increasing reactive oxygen species, and reducing contractile function — a direct cause of the fatigue and exercise intolerance commonly documented in GLP-1 therapy.
Best for: GLP-1 users who want to preserve the quality and metabolic function of the lean mass they retain — not just the quantity; urolithin A addresses the mitochondrial dimension of GLP-1-driven lean mass loss: caloric restriction impairs the mitophagy process that removes dysfunctional mitochondria from muscle cells; Amazentis/Timeline's landmark 2022 JAMA Network Open RCT (n=66, median age 71) showed urolithin A 1,000 mg/day significantly improved muscle strength, endurance, and mitochondrial health biomarkers versus placebo in 4 months; patients losing 20–30 kg on semaglutide or tirzepatide who preserve lean mass quantity via creatine/EAAs/HMB but whose retained muscle has impaired mitochondrial quality will experience reduced exercise capacity, fatigue, and accelerated post-GLP-1 weight regain
Pros
- +JAMA Network Open RCT evidence for strength, endurance, and mitochondrial function improvement in aging adults
- +Addresses mitochondrial quality dimension of lean mass that no other supplement in this stack covers
- +Bypasses gut microbiome dependency for urolithin A conversion — works for all users regardless of microbiome composition
- +Once-daily dosing with no timing requirements
Cons
- −Most expensive supplement in this stack: $3–6/day for 1,000 mg Mitopure
- −8–12 week onset to measurable clinical benefit — requires patience
- −Not a first-line addition — primary stack should be established first
- −Human clinical trial data is primarily in adults 65+; GLP-1-specific data is mechanistic, not direct RCT
Protocol Analysis
Urolithin A (500–1,000 mg/day) — Mitophagy and Mitochondrial Quality Control appears at editorial position #8 because its proposed mechanism is urolithin A preserves lean mass quality during GLP-1 therapy through three mechanisms: (1) PINK1/Parkin-mediated mitophagy activation — urolithin A activates the PINK1/Parkin mitophagy pathway by suppressing CDK1 kinase that normally inhibits PINK1 stabilization on damaged mitochondrial outer membranes; activated PINK1 recruits Parkin E3 ubiquitin ligase, targeting damaged mitochondria for autophagic degradation; urolithin A's PINK1/CDK1 mechanism bypasses the AMPK dependence that caloric restriction impairs, maintaining mitophagy in the energy-restricted state; (2) mitochondrial biogenesis amplification via PGC-1α — urolithin A activates PGC-1α via SIRT1 deacetylase activation; this paired mitophagy (damaged mitochondria removed) + biogenesis (new mitochondria synthesized) response underlies the JAMA Network Open clinical evidence; (3) mTOR/autophagy coordination — urolithin A increases SIRT1 activity, maintaining mitophagy without suppressing mTOR-mediated muscle protein synthesis — the key balance in caloric restriction. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Urolithin A (500–1,000 mg/day) — Mitophagy and Mitochondrial Quality Control is: emerging but highly specific — Andreux et al. 2019 (Nature Metabolism): urolithin A improved mitochondrial gene expression and mitophagy biomarkers in phase 1 human trial; Singh et al. 2022 (JAMA Network Open, n=66, aged 65–90): urolithin A 1,000 mg/day significantly improved 6-minute walk distance, grip strength, and plasma acylcarnitine profiles (mitochondrial function biomarkers) vs placebo at 4 months; GLP-1 context — caloric restriction-induced mitophagy impairment documented in multiple animal studies; urolithin A's mitophagy activation mechanism directly addresses this impairment. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Urolithin A (500–1,000 mg/day) — Mitophagy and Mitochondrial Quality Control are: urolithin A is the most expensive supplement in this stack at $3–6/day for therapeutic doses — establish the creatine + EAAs + protein foundation first; natural urolithin A production from dietary pomegranate polyphenols requires gut microbiome capacity that approximately 50% of adults lack; supplemental urolithin A bypasses this microbiome dependency entirely; expect 8–12 weeks to notice measurable changes in exercise capacity — do not discontinue after 2–4 weeks of no perceived effect. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: GLP-1 users who have established the primary lean mass stack and want to optimize the metabolic quality of their retained lean mass; adults over 50 on GLP-1 therapy where mitophagy impairment is an age-compounding factor; anyone experiencing persistent fatigue or exercise intolerance during GLP-1 therapy not explained by inadequate protein or caloric intake. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Implementation Playbook
- • Clarify the decision first: define the specific GLP-1 lean mass preservation outcome you care about and what evidence would meaningfully change your mind.
- • Check whether the evidence matches your situation: population, baseline status, formulation, comparator, duration, and outcome should be close enough to make the result relevant.
- • Separate study protocol from personal instruction. A dose, schedule, or progression used in a paper describes what was studied; it is not automatically appropriate for an individual reader.
- • Review contraindications, medication interactions, pregnancy considerations, laboratory monitoring needs, and other safety constraints before treating an intervention as actionable.
- • Prefer one clearly defined decision at a time so benefits, adverse effects, and confounders are easier to interpret. For medically consequential interventions, make that decision with a qualified clinician.
- • Predefine what would count as useful, ineffective, or concerning and when the decision should be revisited. Avoid extending an intervention simply because it was ranked highly on this site.
The Verdict
Creatine monohydrate 3–5 g/day holds the first editorial position because it delivers the single highest-return intervention for lean mass preservation during GLP-1-driven caloric restriction — operating through 5 converging mechanisms (PCr-ATP maintenance, satellite cell activation, myostatin suppression, mTORC1 priming, cortisol buffering), costs less than $0.12/day, has zero meaningful drug interactions with semaglutide or tirzepatide, and should be started from day 1 of GLP-1 therapy before lean mass loss begins. That is a comparative judgment about the current evidence and practical context, not a prescription or a guarantee of benefit.
Leucine-enriched EAAs (10–15 g/day) + high-quality protein powder to close the 1.6 g/kg/day gap are the correct escalation, with omega-3 EPA/DHA adding the unique GLP-1 receptor synergy layer via GPR120 signaling is another option worth comparing when its evidence and constraints better match the decision at hand. the GLP-1 lean mass problem is real and measurable — DEXA sub-analyses from STEP-1, SURMOUNT-1, and SURMOUNT-4 consistently show 28–35% of total weight lost is lean mass in absence of intervention; start the supplementation stack on day 1, not after noticing muscle loss, and pair with at least 2 resistance training sessions per week. Treat the ordering as a research aid, then verify population fit, contraindications, alternatives, and objective response with appropriate professional review when the decision is medically consequential.
Related ProtocolRank Articles
Best Protein Powders for GLP-1 Users Ranked 2026
Leucine-optimized protein powders ranked for muscle preservation on GLP-1 caloric restriction — whey isolate, casein, and pea protein evaluated for semaglutide and tirzepatide users.
Best Vitamins for Semaglutide Users Ranked 2026
B12, D3+K2, magnesium, zinc, and omega-3 ranked for the micronutrient gaps created by 30–50% caloric restriction on Ozempic, Wegovy, Mounjaro, and Zepbound.
Best GLP-1 Companion Supplements Ranked 2026
The complete GLP-1 performance stack — protein, electrolytes, fiber, and support ranked for adherence and lean-mass protection on all GLP-1 agonists.
Best Digestive Enzymes for GLP-1 Users Ranked 2026
Enzyme protocols ranked for GLP-1 bloating, sulfur burps, and fat-meal nausea — the complementary GI support stack for semaglutide and tirzepatide users.
Best Fiber Supplements for GLP-1 Constipation Ranked 2026
Psyllium, PHGG, and magnesium glycinate ranked for semaglutide and tirzepatide slow-transit constipation — the #1 GI side effect on GLP-1 therapy.
Best Electrolyte Supplements for GLP-1 Users Ranked 2026
LMNT and electrolyte stacks ranked for the sodium, potassium, and magnesium depletion profile of semaglutide and tirzepatide users.
Best Supplements for Muscle Preservation After 50 Ranked 2026
The broader sarcopenia-prevention stack for aging adults — covers HMB, creatine, EAAs, urolithin A, and D3+K2 in the general over-50 context.
Best Creatine Supplements for Women Ranked 2026
Creatine monohydrate forms ranked for women — particularly relevant for women on GLP-1 therapy where estrogen decline and caloric restriction compound lean mass loss.
Further Reading from Our Sister Sites
Peaked Labs
Peaked Labs: TRT Provider Comparisons
Compare telehealth TRT provider models, monitoring cadence, and total program costs.
Peaked Labs
Peaked Labs: Peptide Provider Pages
Provider-focused peptide therapy breakdowns for screening, sourcing, and follow-up quality.
Peaked Labs
Peaked Labs: Performance Clinic Comparisons
High-intent comparison pages for performance, weight-loss, and optimization clinic pathways.
GLP-1 Muscle Loss Supplements FAQ
Does semaglutide (Ozempic/Wegovy) cause muscle loss?
Yes — STEP-1 DEXA sub-analysis data shows approximately 30% of total weight lost on semaglutide is lean mass (muscle, bone, and organ tissue) rather than fat in the absence of intervention. At a typical 15–20 kg weight loss on semaglutide, this represents 4.5–6 kg of lean mass loss. The mechanism is GLP-1-driven caloric restriction: appetite suppression reduces total intake by 25–50%, reducing anabolic signals (insulin, IGF-1, leucine availability) and increasing catabolic signals (cortisol, UPP activity). Resistance training and the supplementation stack above significantly reduce this lean mass fraction.
Does tirzepatide (Mounjaro/Zepbound) cause more muscle loss than semaglutide?
Tirzepatide produces greater total weight loss than semaglutide (average 22.5% body weight vs 14.9% in SURMOUNT-1 vs STEP-1), but the percentage of lean mass in total weight lost is similar — approximately 29–32% lean fraction in both drug classes. Because tirzepatide produces greater total weight loss, the absolute lean mass loss is larger on tirzepatide. The SURMOUNT-1 DEXA substudy also documented statistically significant hip bone mineral density reduction in the tirzepatide arm — making the D3+K2 addition particularly important for Mounjaro/Zepbound users.
What is the most important supplement for preventing muscle loss on GLP-1?
Creatine monohydrate 3–5 g/day is the most evidence-backed and cost-effective single supplement for lean mass preservation on GLP-1 therapy. It addresses five converging mechanisms: PCr-ATP maintenance, satellite cell activation, myostatin suppression, mTORC1 priming, and cortisol-catabolism buffering. The cost is approximately $0.08–0.12/day for micronized creatine monohydrate powder. Start from day 1 of GLP-1 therapy — not after noticing muscle loss.
Do I need to take all 8 supplements for GLP-1 muscle protection?
No. Build the stack in priority order: (1) Creatine monohydrate — universal, non-negotiable first supplement; (2) High-quality protein powder — if you are not hitting 1.6 g/kg/day from whole food; (3) Leucine-enriched EAAs — to trigger mTORC1 between GLP-1-suppressed meals; (4) Omega-3 EPA/DHA — for GLP-1 receptor synergy and inflammation resolution. This 4-supplement foundation covers the most mechanistically important pathways at reasonable cost. Add HMB-FA if lean mass loss is still occurring, D3+K2 if bone density is a concern, phosphatidylserine if cortisol symptoms are present, and urolithin A for mitochondrial quality optimization in the longer term.
Is creatine safe to take with semaglutide or tirzepatide?
Yes — creatine monohydrate has no documented pharmacological interaction with semaglutide or tirzepatide. At 3–5 g/day maintenance dose, no adverse renal effects occur in adults with normal renal function. Common co-medications for GLP-1 users (metformin, statins, blood pressure medications) have no known interactions with creatine. The initial 0.5–1.5 kg weight gain from creatine's intramuscular water retention is sometimes alarming for GLP-1 users tracking scale weight — this is improved muscle hydration, not fat gain.
Does exercise matter for preventing GLP-1 muscle loss, or do supplements cover it?
Exercise is the primary lean mass preservation intervention — supplements amplify the exercise signal but do not fully replace it. Resistance training 2–3 days/week (even moderate bodyweight or band exercises) markedly improves lean mass preservation on GLP-1 therapy. Creatine's lean mass benefit is 3–4× larger with concurrent resistance training versus creatine alone. Even 20-minute sessions 2×/week of moderate resistance exercise combined with the supplementation stack above significantly shifts the lean-to-fat ratio of GLP-1-driven weight loss.
How much protein do I need daily on semaglutide or tirzepatide to prevent muscle loss?
The minimum for lean mass preservation during caloric restriction is 1.6 g of protein per kg of body weight per day. For optimal preservation during GLP-1 therapy, 2.0–2.2 g/kg/day is the clinical target. For a 75 kg adult, this is 120–165 g protein daily — extremely difficult to achieve from whole foods at 1,200–1,500 kcal/day GLP-1 intake levels. Protein powder (whey isolate or pea protein isolate, 25–30 g/serving) and leucine-enriched EAAs (10–15 g/day) are the practical solutions to this structural gap.
What happens to muscle after stopping GLP-1 medication if I did not protect lean mass during treatment?
GLP-1 weight regain studies consistently show that stopping semaglutide or tirzepatide without behavioral maintenance leads to significant weight regain — typically 50–65% of lost weight at 12 months post-cessation. If lean mass was lost during GLP-1 therapy, the rebuilt tissue tends to be predominantly fat (muscle cannot spontaneously regenerate at the same rate fat deposits), resulting in worse body composition than before GLP-1 therapy despite lower scale weight. This 'worse composition rebound' is the primary argument for aggressive lean mass preservation during GLP-1 therapy rather than treating muscle loss as an acceptable side effect.